Concomitant Treatment of Permanent Atrial Fibrillation (RESTORE SR)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00566787 |
Recruitment Status :
Completed
First Posted : December 4, 2007
Last Update Posted : January 25, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Atrial Fibrillation | Device: Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 39 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Prospective, Multi-center Study With Case Matched Controls to Evaluate the Safety and Efficacy of the AtriCure Bipolar System for the Treatment of Continuous Atrial Fibrillation as Adjunct Therapy to Elective Open Heart Surgery |
Study Start Date : | January 2005 |
Actual Primary Completion Date : | December 2007 |
Actual Study Completion Date : | November 2010 |

- Device: Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
- Primary efficacy endpoint is the proportion of treated patients who are free of atrial fibrillation without the need for anti-arrhythmic agents at the six-month follow-up visit. [ Time Frame: 6 months ]
- The primary safety endpoint is the occurrence of serious adverse events that are considered to be associated with the Maze procedure. [ Time Frame: 30 days ]
- The secondary efficacy endpoint is the proportion of patients in the treatment group who are free of atrial fibrillation independent of the need for anti-arrhythmic drugs. [ Time Frame: 6 Months ]
- The secondary safety endpoints are: total cross clamp time, total time on bypass, length of hospital stay (days), and length of ICU stay (hours) [ Time Frame: Discharge ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or Female subject between 18 to 80 years of age
-
Subject is scheduled to undergo elective cardiac surgical procedure(s) to be performed on cardiopulmonary bypass including:
- coronary artery bypass and/or
- mitral valve surgery (repair or replacement)
- aortic valve surgery (repair or replacement)
- tricuspid valve surgery (repair or replacement)
- Left Ventricular Ejection Fraction ≥ 30%
- Subject is willing and able to provide written informed consent
- Subject has a life expectancy of at least 2 years
- Subject is willing and able to return for scheduled follow-up visits
- TREATMENT SUBJECTS ONLY: Subject has a 3 month documented history of continuous atrial fibrillation
- CONTROL SUBJECTS ONLY: Subject is not in atrial fibrillation at time of surgery
Exclusion Criteria:
- Lone AF without indication(s) for concomitant CABG and/or mitral valve surgery, aortic valve surgery, tricuspid valve surgery or double valve surgery
- Prior cardiac surgery (Redo -including previous ablation)
- Patient requires atrial septal defect repair or any other concomitant open-heart procedure, other than CABG and/or mitral valve surgery; aortic valve surgery, tricuspid valve surgery or double valve surgery
- Serum creatinine concentration greater than 2.0 mg/dl
- Class IV NYHA heart failure symptoms and/or Class IV CCS anginal symptoms
- Prior history of cerebrovascular accident within 6 months or at any time if there is residual neurologic deficit
- Active infection
- Known carotid artery stenosis greater than 80%
- Severe peripheral arterial occlusive disease defined as claudication with minimal exertion
- A known drug and/or alcohol addiction
- Mental impairment or other conditions which may not allow the the subject to understand the nature, significance and scope of the study
- Pregnancy or desire to get pregnant within 12 months of study enrollment
- Requires anti-arrhythmic drug therapy for the treatment of a ventricular arrhythmia

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00566787
United States, Indiana | |
Heart Center of Indiana | |
Indianapolis, Indiana, United States, 46290 | |
United States, Michigan | |
University of Michigan | |
Ann Arbor, Michigan, United States, 48109 | |
Spectrum Health | |
Grand Rapids, Michigan, United States, 49506 | |
United States, Minnesota | |
Mayo Clinic | |
Rochester, Minnesota, United States, 55902 | |
United States, Missouri | |
Washington University | |
St. Louis, Missouri, United States, 63110 | |
United States, Ohio | |
Cleveland Clinic | |
Cleveland, Ohio, United States, 44195 | |
United States, Texas | |
The Methodist Hospital | |
Houston, Texas, United States, 77030 | |
United States, Virginia | |
Sentara Norfolk Hospital | |
Norfolk, Virginia, United States, 23507 | |
United States, Washington | |
Sacred Heart Medical Center | |
Seattle, Washington, United States, 99220 | |
United States, Wisconsin | |
St. Mary's Hospital Medical Center | |
Madison, Wisconsin, United States, 53715 |
Principal Investigator: | A. Marc Gillinov, MD | The Cleveland Clinic |
Responsible Party: | AtriCure, Inc. |
ClinicalTrials.gov Identifier: | NCT00566787 |
Other Study ID Numbers: |
CP2003-1 |
First Posted: | December 4, 2007 Key Record Dates |
Last Update Posted: | January 25, 2012 |
Last Verified: | January 2012 |
AF Atrial Fibrillation afib racing heart cabg |
valve ablation bipolar radiofrequency rf |
Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes |